Logo image of HSTO

HISTOGEN INC (HSTO) Stock Fundamental Analysis

NASDAQ:HSTO - Nasdaq - US43358Y2028 - Common Stock - Currency: USD

0.658  +0.15 (+29.27%)

After market: 0.6531 0 (-0.74%)

Fundamental Rating

3

HSTO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 559 industry peers in the Biotechnology industry. The financial health of HSTO is average, but there are quite some concerns on its profitability. While showing a medium growth rate, HSTO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year HSTO has reported negative net income.
HSTO had a negative operating cash flow in the past year.
In the past 5 years HSTO always reported negative net income.
In the past 5 years HSTO always reported negative operating cash flow.
HSTO Yearly Net Income VS EBIT VS OCF VS FCFHSTO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M

1.2 Ratios

HSTO has a worse Return On Assets (-89.51%) than 75.58% of its industry peers.
Looking at the Return On Equity, with a value of -130.43%, HSTO is doing worse than 66.50% of the companies in the same industry.
Industry RankSector Rank
ROA -89.51%
ROE -130.43%
ROIC N/A
ROA(3y)-79.39%
ROA(5y)-75.22%
ROE(3y)-128.82%
ROE(5y)-120.14%
ROIC(3y)N/A
ROIC(5y)N/A
HSTO Yearly ROA, ROE, ROICHSTO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -50 -100 -150 -200

1.3 Margins

HSTO has a Gross Margin of 19836.80%. This is amongst the best in the industry. HSTO outperforms 100.00% of its industry peers.
HSTO's Gross Margin has improved in the last couple of years.
HSTO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 19836.8%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.8%
GM growth 5YN/A
HSTO Yearly Profit, Operating, Gross MarginsHSTO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -1K -2K -3K

More info and screens

6

2. Health

2.1 Basic Checks

HSTO does not have a ROIC to compare to the WACC, probably because it is not profitable.
HSTO has more shares outstanding than it did 1 year ago.
HSTO has a better debt/assets ratio than last year.
HSTO Yearly Shares OutstandingHSTO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M
HSTO Yearly Total Debt VS Total AssetsHSTO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M

2.2 Solvency

HSTO has an Altman-Z score of -11.61. This is a bad value and indicates that HSTO is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of HSTO (-11.61) is worse than 81.35% of its industry peers.
HSTO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.61
ROIC/WACCN/A
WACC9.53%
HSTO Yearly LT Debt VS Equity VS FCFHSTO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M

2.3 Liquidity

A Current Ratio of 8.54 indicates that HSTO has no problem at all paying its short term obligations.
HSTO's Current ratio of 8.54 is fine compared to the rest of the industry. HSTO outperforms 66.67% of its industry peers.
HSTO has a Quick Ratio of 8.54. This indicates that HSTO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 8.54, HSTO is in the better half of the industry, outperforming 66.83% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.54
Quick Ratio 8.54
HSTO Yearly Current Assets VS Current LiabilitesHSTO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 41.01% over the past year.
Looking at the last year, HSTO shows a very negative growth in Revenue. The Revenue has decreased by -99.56% in the last year.
The Revenue for HSTO have been decreasing by -36.10% on average. This is quite bad
EPS 1Y (TTM)41.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.39%
Revenue 1Y (TTM)-99.56%
Revenue growth 3Y-30.95%
Revenue growth 5Y-36.1%
Sales Q2Q%0%

3.2 Future

The Earnings Per Share is expected to grow by 30.21% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 85.81% on average over the next years. This is a very strong growth
EPS Next Y26.45%
EPS Next 2Y9.45%
EPS Next 3Y4.01%
EPS Next 5Y30.21%
Revenue Next Year-99.88%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y85.81%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
HSTO Yearly Revenue VS EstimatesHSTO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
HSTO Yearly EPS VS EstimatesHSTO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -100 -200 -300

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

HSTO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HSTO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HSTO Price Earnings VS Forward Price EarningsHSTO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HSTO Per share dataHSTO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.45%
EPS Next 3Y4.01%

More info and screens

0

5. Dividend

5.1 Amount

HSTO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HISTOGEN INC

NASDAQ:HSTO (10/4/2023, 8:13:37 PM)

After market: 0.6531 0 (-0.74%)

0.658

+0.15 (+29.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-10 2023-08-10/amc
Earnings (Next)11-08 2023-11-08/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners2.77%
Ins Owner Change0%
Market Cap2.81M
Analysts85.71
Price Target2.04 (210.03%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)21.07%
Min EPS beat(2)-4.49%
Max EPS beat(2)46.62%
EPS beat(4)3
Avg EPS beat(4)21.96%
Min EPS beat(4)-4.49%
Max EPS beat(4)46.62%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)44.9%
EPS NY rev (1m)0%
EPS NY rev (3m)30.77%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 147.88
P/FCF N/A
P/OCF N/A
P/B 0.3
P/tB 0.3
EV/EBITDA N/A
EPS(TTM)-2.92
EYN/A
EPS(NY)-2.7
Fwd EYN/A
FCF(TTM)-2.31
FCFYN/A
OCF(TTM)-2.3
OCFYN/A
SpS0
BVpS2.18
TBVpS2.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -89.51%
ROE -130.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 19836.8%
FCFM N/A
ROA(3y)-79.39%
ROA(5y)-75.22%
ROE(3y)-128.82%
ROE(5y)-120.14%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.8%
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.62%
Cap/Sales 52.63%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.54
Quick Ratio 8.54
Altman-Z -11.61
F-Score3
WACC9.53%
ROIC/WACCN/A
Cap/Depr(3y)150.91%
Cap/Depr(5y)126.1%
Cap/Sales(3y)10.5%
Cap/Sales(5y)6.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.39%
EPS Next Y26.45%
EPS Next 2Y9.45%
EPS Next 3Y4.01%
EPS Next 5Y30.21%
Revenue 1Y (TTM)-99.56%
Revenue growth 3Y-30.95%
Revenue growth 5Y-36.1%
Sales Q2Q%0%
Revenue Next Year-99.88%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y85.81%
EBIT growth 1Y-9.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y37.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.54%
OCF growth 3YN/A
OCF growth 5YN/A